AZD7442 reduced the risk of developing symptomatic Covid-19 by 33% compared to a placebo, which was not statistically significant, the company reported. AstraZeneca is also studying the treatment in a pre-exposed patients trial and for preventing more severe disease.from UK News Headlines, Latest UK News and Live Updates - Times of India https://ift.tt/2Ssv0hC
No comments:
Post a Comment